NeoGenomics To Present New Data At San Antonio Breast Cancer Symposium Highlighting Utility Of RaDaR For Therapy Response
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics, Inc. (NASDAQ:NEO) will present new data on its RaDaR assay for minimal residual disease (MRD) at the San Antonio Breast Cancer Symposium. The data includes an updated analysis of the TRACER study, which evaluates the use of RaDaR in early-stage breast cancer for therapy response monitoring and post-operative recurrence. The company also announced the receipt of the first samples from the SURVIVE clinical trial, which uses RaDaR for recurrence monitoring. RaDaR is a highly sensitive, tumor-informed assay that has received Breakthrough Device Designation by the US FDA and the CE mark.
December 05, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics' presentation of new RaDaR assay data at SABCS and the receipt of samples from the SURVIVE trial may positively influence investor perception, highlighting the assay's clinical utility and regulatory achievements.
The presentation of new data at a major symposium and the progress in a significant clinical trial are likely to be viewed positively by investors, as they demonstrate the clinical utility and potential market growth of the RaDaR assay. The FDA Breakthrough Device Designation and CE mark further underscore the regulatory success and may lead to increased adoption in clinical settings.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100